NYSE:MED - Medifast Stock Price, Forecast & News

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast declared a quarterly dividend on Thursday, December 5th. Stockholders of record on Friday, December 27th will be given a dividend of $1.13 per share on Thursday, February 6th. This represents a $4.52 annualized dividend and a dividend yield of 3.91%. The ex-dividend date is Thursday, December 26th. This is an increase from Medifast's previous quarterly dividend of $0.75. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) issued its earnings results on Thursday, November, 7th. The specialty retailer reported $1.32 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.33 by $0.01. The specialty retailer had revenue of $190.10 million for the quarter, compared to analyst estimates of $194.70 million. Medifast had a net margin of 10.70% and a return on equity of 62.93%. The firm's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Medifast.

Medifast issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of $5.80-5.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.83. The company issued revenue guidance of $$700-710 million, compared to the consensus revenue estimate of $$750.45 million.

4 equities research analysts have issued 12 month price objectives for Medifast's shares. Their forecasts range from $74.00 to $216.00. On average, they anticipate Medifast's stock price to reach $140.00 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Medifast.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

News coverage about MED stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Medifast.

Medifast saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 4,110,000 shares, a drop of 8.9% from the December 15th total of 4,510,000 shares. Based on an average daily trading volume, of 408,800 shares, the short-interest ratio is presently 10.1 days. Approximately 36.7% of the company's shares are sold short. View Medifast's Current Options Chain.

Some companies that are related to Medifast include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Paypal (PYPL), Home Depot (HD), Adobe (ADBE), Mastercard (MA), Boeing (BA), Lululemon Athletica (LULU) and Baidu (BIDU).

Medifast's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (0.54%), Winmill & CO. Inc. (0.34%), Chickasaw Capital Management LLC (0.28%), State of Alaska Department of Revenue (0.08%), Nisa Investment Advisors LLC (0.04%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Medifast stock include Carl E Sassano, Charles P Connolly, Constance J Hallquist, Daniel R Chard, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Chickasaw Capital Management LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Medifast company stock in the last year include Carl E Sassano and Scott Schlackman. View Insider Buying and Selling for Medifast.

MED stock was acquired by a variety of institutional investors in the last quarter, including Winmill & CO. Inc., Ingalls & Snyder LLC, Nisa Investment Advisors LLC and FormulaFolio Investments LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard and Michael A Hoer. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $115.66.

Medifast has a market capitalization of $1.34 billion and generates $501 million in revenue each year. The specialty retailer earns $55.79 million in net income (profit) each year or $4.62 on an earnings per share basis. Medifast employs 420 workers across the globe.View Additional Information About Medifast.

The official website for Medifast is http://www.medifast1.com/.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]